{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:50:51Z","timestamp":1781769051893,"version":"3.54.5"},"reference-count":56,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO 2155\/7-1"],"award-info":[{"award-number":["KO 2155\/7-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BR 1782\/5-1"],"award-info":[{"award-number":["BR 1782\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Interdisciplinary Center for Clinical Research, Faculty of Medicine, RWTH Aachen University","award":["IZKF O3-7"],"award-info":[{"award-number":["IZKF O3-7"]}]},{"name":"Stiftung Universit\u00e4tsmedizin of RWTH Aachen University","award":["KK, THB, and SK"],"award-info":[{"award-number":["KK, THB, and SK"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Inflammation-induced thrombosis represents a severe complication in patients with myeloproliferative neoplasms (MPN) and in those with kidney dysfunction. Overlapping disease-specific attributes suggest common mechanisms involved in MPN pathogenesis, kidney dysfunction, and thrombosis. Data from 1420 patients with essential thrombocythemia (ET, 33.7%), polycythemia vera (PV, 38.5%), and myelofibrosis (MF, 27.9%) were extracted from the bioregistry of the German Study Group for MPN. The total cohort was subdivided according to the calculated estimated glomerular filtration rate (eGFR, (mL\/min\/1.73 m2)) into eGFR1 (\u226590, 21%), eGFR2 (60\u201389, 56%), and eGFR3 (&lt;60, 22%). A total of 29% of the patients had a history of thrombosis. A higher rate of thrombosis and longer MPN duration was observed in eGFR3 than in eGFR2 and eGFR1. Kidney dysfunction occurred earlier in ET than in PV or MF. Multiple logistic regression analysis identified arterial hypertension, MPN treatment, increased uric acid, and lactate dehydrogenase levels as risk factors for kidney dysfunction in MPN patients. Risk factors for thrombosis included arterial hypertension, non-excessive platelet counts, and antithrombotic therapy. The risk factors for kidney dysfunction and thrombosis varied between MPN subtypes. Physicians should be aware of the increased risk for kidney disease in MPN patients, which warrants closer monitoring and, possibly, early thromboprophylaxis.<\/jats:p>","DOI":"10.3390\/cancers13164086","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T09:22:38Z","timestamp":1628846558000},"page":"4086","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9523-295X","authenticated-orcid":false,"given":"Judith","family":"Gecht","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology and SCT, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany"},{"name":"Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD), 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tsoukakis","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology and SCT, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany"},{"name":"Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD), 52074 Aachen, Germany"},{"name":"Department of Medicine, Hematology\/Oncology, Goethe-University, 60590 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3102-2221","authenticated-orcid":false,"given":"Kim","family":"Kricheldorf","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology and SCT, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany"},{"name":"Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD), 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Stegelmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital of Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Klausmann","sequence":"additional","affiliation":[{"name":"Studienzentrum Aschaffenburg, 63739 Aschaffenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[{"name":"Johannes Wesling Medical Center, University Clinic for Hematology, Oncology, Hemostaseology, and Palliative Care (UKRUB), University of Bochum, 32429 Minden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Schulz","sequence":"additional","affiliation":[{"name":"Oncological Practice, 50226 Frechen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Hollburg","sequence":"additional","affiliation":[{"name":"HOPA-H\u00e4matologisch-Onkologische Praxis Altona, 22767 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim R.","family":"G\u00f6thert","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, University Hospital Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Sockel","sequence":"additional","affiliation":[{"name":"Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[{"name":"Innere Medizin C, Universit\u00e4tsmedizin Greifswald, 17475 Greifswald, Germany"},{"name":"Department of Hematology\/Oncology, Clinic of Internal Medicine II, Jena University Hospital, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Gattermann","sequence":"additional","affiliation":[{"name":"Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD), 52074 Aachen, Germany"},{"name":"Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University D\u00fcsseldorf, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Maintz","sequence":"additional","affiliation":[{"name":"MWZ-West Hematology-Oncology, 52146 W\u00fcrselen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa K.","family":"Al-Ali","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University Hospital Halle, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cellular Therapy, Medical Clinic and Policlinic I, Leipzig University Hospital, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hansen","sequence":"additional","affiliation":[{"name":"Oncological Practice Dres. Hansen & Reeb, 67655 Kaiserslautern, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Klinikum Chemnitz, 09116 Chemnitz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefani","family":"Parmentier","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Rems-Murr-Klinikum Winnenden, 71364 Winnenden, Germany"},{"name":"Onkologie\/H\u00e4matologie, Claraspital Tumorzentrum Basel, 4058 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bommer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Infectious Diseases and Palliative Care, Alb-Fils-Kliniken, 73035 G\u00f6ppingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike L.","family":"Pahl","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Hematology and Oncology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology\/Oncology, Goethe-University, 60590 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kirschner","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology and SCT, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany"},{"name":"Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD), 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Isfort","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology and SCT, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany"},{"name":"Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD), 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology and SCT, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany"},{"name":"Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD), 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital of Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology and SCT, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany"},{"name":"Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD), 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): Analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","first-page":"101","article-title":"Thrombotic and bleeding complications in classical myeloproliferative neoplasms","volume":"39","author":"McMahon","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/leu.2011.314","article-title":"Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera","volume":"26","author":"Reikvam","year":"2012","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Price, G.L., Davis, K.L., Karve, S., Pohl, G., and Walgren, R.A. (2014). Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090299"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: Analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00277-019-03625-x","article-title":"Thromboembolic events in polycythemia vera","volume":"98","author":"Griesshammer","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0033-1343890","article-title":"JAK2 mutation-related disease and thrombosis","volume":"39","author":"Vannucchi","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/cam4.2886","article-title":"Thrombosis among 1537 patients with JAK2(V617F) -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"ref_14","first-page":"2918","article-title":"Cardiovascular disease and its relationship with chronic kidney disease","volume":"18","author":"Liu","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.kint.2016.09.049","article-title":"Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: A review","volume":"91","author":"Mathew","year":"2017","journal-title":"Kidney Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fcell.2019.00314","article-title":"Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale","volume":"7","author":"Provenzano","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic Kidney Disease and Mortality Risk: A Systematic Review","volume":"17","author":"Tonelli","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jama.2010.39","article-title":"Relation between kidney function, proteinuria, and adverse outcomes","volume":"303","author":"Hemmelgarn","year":"2010","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/jth.12141","article-title":"Risk of venous thrombosis in patients with chronic kidney disease: Identification of high-risk groups","volume":"11","author":"Ocak","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1523-1755.2005.00455.x","article-title":"C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease","volume":"68","author":"Menon","year":"2005","journal-title":"Kidney Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10157-003-0250-2","article-title":"Fibrillary glomerulonephritis associated with essential thrombocytosis","volume":"7","author":"Asaba","year":"2003","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5414\/CNP68412","article-title":"Focal segmental glomerulosclerosis associated with polycythemia vera: Report of a case and review of the literature","volume":"68","author":"Okuyama","year":"2007","journal-title":"Clin. Nephrol."},{"key":"ref_23","first-page":"5086963","article-title":"A Case of Essential Thrombocythemia and IgA Nephropathy with Literature Review of the Concurrence","volume":"2019","author":"Rahimian","year":"2019","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.leukres.2014.01.014","article-title":"Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms","volume":"38","author":"Christensen","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3904\/kjim.2016.263","article-title":"Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: A single-center retrospective study","volume":"33","author":"Baek","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12185-020-02898-7","article-title":"Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera","volume":"112","author":"Holik","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s00277-020-04239-4","article-title":"Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis","volume":"99","author":"Lucijanic","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00277-019-03708-9","article-title":"Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis","volume":"98","author":"Strati","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.3324\/haematol.2018.208876","article-title":"Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy","volume":"104","author":"Fukuda","year":"2019","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ki.2013.444","article-title":"Summary of KDIGO 2012 CKD Guideline: Behind the scenes, need for guidance, and a framework for moving forward","volume":"85","author":"Levin","year":"2014","journal-title":"Kidney Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3324\/haematol.2015.129239","article-title":"Therapeutic effect of androgen therapy in a mouse model of aplastic anemia produced by short telomeres","volume":"100","author":"Bar","year":"2015","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: A study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden","volume":"84","author":"Reverter","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.22264","article-title":"Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146+ immunomagnetic enrichment\u2014Flow cytometry and soluble E-selectin detection","volume":"87","author":"Belotti","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ajh.25713","article-title":"Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets","volume":"95","author":"Hauschner","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.ki.5002017","article-title":"Risk factors for chronic kidney disease in a community-based population: A 10-year follow-up study","volume":"71","author":"Yamagata","year":"2007","journal-title":"Kidney Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1001\/archinte.168.20.2212","article-title":"Rapid kidney function decline and mortality risk in older adults","volume":"168","author":"Rifkin","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1681\/ASN.2020030323","article-title":"The Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study","volume":"32","author":"Hapca","year":"2020","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6232909","DOI":"10.1155\/2016\/6232909","article-title":"Acute Kidney Injury in Diabetes Mellitus","volume":"2016","author":"Patschan","year":"2016","journal-title":"Int. J. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.leukres.2012.07.009","article-title":"Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance","volume":"36","author":"Skov","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2215\/CJN.00950208","article-title":"Aspects of immune dysfunction in end-stage renal disease","volume":"3","author":"Kato","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.2215\/CJN.00710111","article-title":"C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients","volume":"6","author":"Bazeley","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1681\/ASN.2008010080","article-title":"Elevated uric acid increases the risk for kidney disease","volume":"19","author":"Obermayr","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MNH.0000000000000079","article-title":"JAK inhibition and progressive kidney disease","volume":"24","author":"Brosius","year":"2015","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1007\/s00125-016-4021-5","article-title":"JAK inhibition in the treatment of diabetic kidney disease","volume":"59","author":"Brosius","year":"2016","journal-title":"Diabetologia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/10428194.2013.797086","article-title":"Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney disease","volume":"55","author":"Tabarroki","year":"2014","journal-title":"Leuk. Lymphoma."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/10428194.2018.1474525","article-title":"Renal complications of primary myelofibrosis","volume":"60","author":"Strati","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00277-014-2224-8","article-title":"Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: Consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.)","volume":"93","author":"Kreher","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: A systematic review and meta-analysis","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood.2019003347","article-title":"Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis","volume":"135","author":"Ronner","year":"2020","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/01.mnh.0000247505.71915.05","article-title":"Serum cystatin C as a marker of glomerular filtration rate","volume":"15","author":"Madero","year":"2006","journal-title":"Curr. Opin. Nephrol. Hypertens."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/16\/4086\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:45:42Z","timestamp":1760165142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/16\/4086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":56,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["cancers13164086"],"URL":"https:\/\/doi.org\/10.3390\/cancers13164086","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]}}}